Systematic review: antihypertensive drug therapy in patients of African and South Asian ethnicity

Lizzy M. Brewster1,2 · Gert A. van Montfrans1,2 · Glenn P. Oehlers3 · Yackoob K. Seedat4

Received: 9 December 2015 / Accepted: 22 February 2016 / Published online: 30 March 2016
© The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract Despite the large differences in the epidemiology of hypertension across Europe, treatment strategies are similar for national populations of white European descent. However, hypertensive patients of African or South Asian ethnicity may require ethnic-specific approaches, as these population subgroups tend to have higher blood pressure at an earlier age that is more difficult to control, a higher occurrence of diabetes, and more target organ damage with earlier cardiovascular mortality. Therefore, we systematically reviewed the evidence on antihypertensive drug treatment in South Asian and African ethnicity patients. We used the Cochrane systematic review methodology to retrieve trials in electronic databases including CENTRAL, PubMed, and Embase from their inception through November 2015; and with handsearch. We retrieved 4596 reports that yielded 35 trials with 7 classes of antihypertensive drugs in 25,540 African ethnicity patients. Aside from the well-known blood pressure efficacy of calcium channel blockers and diuretics, with lesser effect of ACE inhibitors and beta-blockers, nebivolol was not more effective than placebo in reducing systolic blood pressure levels. Trials with morbidity and mortality outcomes indicated that lisinopril and losartan-based therapy were associated with a greater incidence of stroke and sudden death. Furthermore, 1581 reports yielded 16 randomized controlled trials with blood pressure outcomes in 1719 South Asian hypertensive patients. In contrast with the studies in African ethnicity patients, there were no significant differences in blood pressure lowering efficacy between drugs, and no trials available with mortality outcomes. In conclusion, in patients of African ethnicity, treatment initiated with ACE inhibitor or angiotensin II receptor blocker monotherapy was associated with adverse cardiovascular outcomes. We found no evidence of different efficacy of antihypertensive drugs in South Asians, but there is a need for trials with morbidity and mortality outcomes. Screening for cardiovascular risk at a younger age, treating hypertension at lower thresholds, and new delivery models to find, treat and follow hypertensives in the community may help reduce the excess cardiovascular mortality in these high-risk groups.

Keywords Hypertension · Antihypertensive drugs · Systematic review · African continental ancestry group · South Asian · Ethnic groups

Background

The increasing ethnic diversity of the European population is likely to bring a greater diversity in disease and disease patterns to the doctor’s office. Around 33 million immigrants live in the European Union. It is estimated that a third of these immigrants are from other European countries, while immigrants from non-European countries are mainly African (25 %, with more than half North-African), or Asian (21 %) [1].
Despite the large differences in the epidemiology of hypertension across Europe [2], treatment strategies tend to be similar for national populations of white European descent. Nevertheless, in particular patients of South Asian and sub-Saharan African descent tend to have more hypertension and diabetes, and more target organ damage and cardiovascular mortality at a younger age than patients of white European descent. In addition, hypertension occurs earlier in life in these patients groups, bringing about a faster progression from normotension to hypertension, with higher mean blood pressures than in white patients [3–22].

While little is reported regarding the pathophysiology of hypertension in South Asian patients, abundant data in patients of African descent indicate there is greater salt sensitivity, blunted nocturnal dipping, and enhanced vasoconstriction in this group [3–8, 10, 12–14, 16–21]. South Asians are genetically diverse, but members of this population subgroup share a high cardiovascular risk, with more severe atherosclerosis reported, and ischaemic end organ damage at a younger age even with lower cholesterol levels than in whites [11]. Thus, hypertension seems to be a more aggressive disease, occurring at a younger age in these patient groups. This could have important implications for hypertension screening and management.

In patients of all ethnicity groups, non-pharmacological intervention to reduce hypertension and cardiovascular risk, including dietary adjustments, physical exercise, weight reduction, smoking cessation, and reduction of excessive alcohol intake should be part of hypertension management. In addition, stress reduction and relaxation exercise might aid in reducing blood pressure [23]. In particular, diets high in potassium and calcium and low in sodium, such as the (DASH) diet, have documented blood pressure lowering efficacy [24–30]. These measures are thought to be effective in hypertensives across ethnic groups, but increasing evidence indicates that the very low salt intake (<1500 mg or <65 mmol sodium per day) recommended for persons of African ethnicity [31–33], has been associated with increased mortality in this group, potentially related to activation of the renin angiotensin system [31, 32]. Even so, high salt intake (>2300 mg or >100 mmol sodium per day) is still considered detrimental to cardiovascular health [32], and moderate salt restriction continues to have a place in the management of hypertension in all ethnic groups.

However, most patients with hypertension will need drug therapy aside life style measures. Therefore, in this paper, we review the evidence on randomized trials of antihypertensive drug treatment in African and South Asian ethnicity patients, and propose practical approaches for the European situation.

Methods

The participation of patients of ethnic minority groups in major, international clinical trials is generally too low to calculate the primary outcome with sufficient power [34]. Therefore, we systematically reviewed the evidence on the efficacy of antihypertensive drug therapy to reduce blood pressure and morbidity and mortality outcomes, and pooled the existing data.

Systematic searches were conducted in November 2015, with our previous systematic review on patients of African ethnicity [16, 17] updated and expanded. In brief, we used the Cochrane systematic review methodology, [35] and defined a highly sensitive search strategy to retrieve original reports of randomized controlled trials in hypertensive African and South Asian ethnicity patients, providing original quantitative data on the effect of antihypertensive monotherapy on blood pressure (trial duration at least 2 weeks) vs concurrent placebo treatment, or antihypertensive mono or combination therapy on morbidity or mortality outcomes (trial duration at least 1 year).

We included only trials with major drug classes in adults, men and non-pregnant women, with uncomplicated primary hypertension (no history of, or current cardiovascular events or ESRD). Trials that considered oral antihypertensive treatment with thiazide and thiazide-like diuretics, calcium-channel blockers, centrally acting agents, peripheral adrenergic neuron antagonists, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin II receptor blockers were eligible for inclusion.

We conducted separate searches and data analysis for these two ethnic groups. Searches were performed in electronic databases (Embase, PubMed, Cochrane Library CENTRAL, Literatura Latino-Americana y del Caribe en Ciencias de la Salud (LILACS), African Index Medicus, and for South Asian patients, IndMED) from their inception through November 2015, without language restriction.

These databases have different software and therefore different search languages, but a typical search strategy for trials in patients of African ethnicity was, “(Black* OR Afri* OR AFRO* OR Creole OR Carribean OR Caribbean OR negr* OR ethnic* OR blacks) AND (hypertension OR antihypertensive) AND randomized”; and for South Asians: the first step was “(South Asian OR South Asians OR India OR Indian OR Hindustani OR Bangladesh OR Nepal OR Sri Lanka OR Ceylon OR Pakistan)”.

Search yields from all databases were considered and analysed separately to prevent merging errors and to enhance trial retrieval. Furthermore, we contacted experts and performed hand search. We did not include trials in diabetics only, with experimental drugs, or with complementary medicines.
We used data extraction forms to collect trial data. With pilot searches, we retrieved very few placebo controlled trials in South Asians, and decided to review drug vs drug trials in this group. For drug vs drug trials with multiple treatment arms, we followed the Cochrane handbook methodology and combined the comparison groups into one group of “other drugs” [35]. African or South Asian descent (ancestry, or ethnicity) were defined as respectively of sub-Saharan African descent, or Indian subcontinental descent as indicated by the authors. We included only randomized controlled trials, and methodological quality was further assessed using the Jadad score, based on the description of randomization, blinding, and accountability of all patients, including withdrawals in each of the study groups, and the underlying reasons. Subgroups were based on gender and geographical location, and compliance data were assessed in trials with mortality outcomes.

**Statistical analysis**

Quantitative analysis of outcomes was based on intention-to-treat results (primary) and per protocol analysis (secondary). We included data from the first part of crossover studies when such data were available; if not, we included the data these studies provided. Our measure of effect for each study was difference in means (in mmHg) for systemic arterial blood pressure (continuous measure) and relative risk (RR) for dichotomous data. In addition, we calculated achievement of target diastolic blood pressure (DBP) or reduction of ≥10 mmHg, or ≥10 %, as defined by the author) as the weighted mean of placebo-corrected results per drug class, or in South Asians, vs other drug types.

Missing standard deviations were imputed per drug class. We clinically assessed studies for heterogeneity in patient characteristics, interventions, and outcomes, to decide whether studies should be pooled. Furthermore, we used $I^2$ statistics to quantify the proportion of total variation in the estimates of treatment effect that was due to heterogeneity. We planned to not aggregate results with a high variation across studies ($I^2 \geq 75 \%$) [17, 35]. When we aggregated studies, we conservatively used the random effects model to estimate the average intervention effect. Data in square brackets are 95% confidence intervals, unless indicated otherwise. We used Review Manager (RevMan) software, version 5 (Cochrane Collaboration, Oxford, UK) for the analyses.

**Results**

**Patients of African ethnicity**

Full reports or abstracts from 4596 references of papers yielded 35 trials with 7 classes of antihypertensive drugs, in 25,540 patients. Blood pressure was the main outcome measure in 28 of these trials (Figs. 1, 2; Table 1) [36–66], and morbidity or mortality in seven trials (Table 2) [67–88]. Our 2015 update included two new trials with blood pressure outcomes on nebivolol [46, 53], and eight new reports on morbidity and mortality outcomes (five reports with new subgroup analyses from the ALLHAT and LIFE, and AASK trials, and three new reports of the VALUE, INVEST, and ACCOMPLISH trials) [81–88]. Trials were clinically comparable in describing the results of randomized controlled interventions with antihypertensive drugs in African ethnicity patients with hypertension, but the age range, inclusion blood pressure, drugs and drug dose varied (Tables 1, 2). Since we retrieved only two new blood pressure trials considering monotherapy with nebivolol vs placebo, the results of the 2015 update are similar to the data reported previously, as depicted in Fig. 2a, b. As a post hoc outcome, nebivolol was analysed separately as well because of the presumed different mechanism of action [46, 53]. Nebivolol is thought to enhance nitric oxide generation [46, 53]. However, the pooled weighted mean difference in systolic (SBP) and diastolic pressure vs placebo of these two trials is respectively SBP $-3.38$ mmHg, 95% CI $[-8.38; 1.62]$; $I^2$ 33%; and DBP $-5.00$ mmHg, 95% CI $[-7.41; -2.59]$ ($I^2$ = 0%). With the addition of these relatively large trials to the pooled analysis (Fig. 2a) the size of the effect of beta-adrenergic blockers on systolic blood pressure was similar, but the confidence interval became narrower, and statistically significant from placebo [pooled estimate for systolic blood pressure without nebivolol $-3.53 [-7.51; 0.45]$ ($I^2 = 50 \%$) [17], and with nebivolol $-3.73 [-6.80; -0.66] (I^2 = 44 \%$), Fig. 2a].

Achievement of target DBP differed by drug class, calcium-channel blockers 46% (RR 3.39 [2.35; 4.90]; diuretics 31% (RR 2.49 [1.68; 3.69]; beta-adrenergic blockers 24% (RR 1.97 [1.43; 2.72]; centrally acting agents 23% (RR 2.22 [1.35; 3.63]; angiotensin II receptor blockers 19% (1.77 [1.41; 2.21]; alpha-blockers 13% (RR 1.71 [1.02; 2.86]; and ACE inhibitors 10% (RR 1.35 (0.81; 2.26); with a RR of >1.0 indicating a beneficial effect.

Thus, the aggregated data show a greater effect of calcium blockers and diuretics, while beta-adrenergic blockers and ACE inhibitors are the least effective drugs to lower SBP and DBP, respectively. The cause of these differences in drug responses is largely unknown. Our findings are in accord with the suppressed activity of the renin-angiotensin-aldosterone system in hypertensive patients of African ethnicity, and the high activity of creatine kinase, promoting vasoconstriction and salt retention [8, 16]. As a consequence, patients of African ethnicity are significantly less sensitive to drugs that block the renin-angiotensin system (angiotensin-converting enzyme inhibitors and
angiotensin II receptor blockers) and beta-blockers [16]. Genetic and pharmacokinetic differences do not fully explain these differences [16], but altered cellular functions based on high creatine kinase activity and enhanced phosphoryl group buffer function have been implied in this group, leading to enhanced ATP-dependent responses including greater contractility, salt retention and therapy failure [16, 18], as well as lower NO bioavailability [8, 16].

We predefined subgroups based on gender and on geographical location. However, only 3 small trials out of 28 trials with blood pressure outcomes reported data for men and women (N = 146 patients), and this was not further analysed [40, 45, 66]. When we separately analysed US/Caribbean studies, calcium-channel blockers changed SBP by −11.89 mmHg (CI −14.12 to −9.67 mmHg) and beta-blockers led to a change of −4.83 mmHg (CI −7.91 to −1.75 mmHg); the size of the effect of alpha-blockers on DBP became heterogeneous. When we separately analysed data from African studies, however, only calcium-channel blockers remained more effective than placebo for all outcomes analysed. Diuretics did not significantly differ from placebo in achieving the DBP goal (relative risk 3.55

![Diagram of trial flow](https://example.com/diagram.png)
[CI 0.41–31.05]), and ACE inhibitors, beta-blockers, and alpha-blockers did not significantly differ from placebo in reduction of SBP and DBP. None of the African studies used a cutoff baseline DBP of less than 114 mmHg, compared with 7 of the 15 US and Caribbean studies (Table 1). Thus, we could not determine whether the response of African patients truly differed from that of US and Caribbean patients or was rather related to higher baseline blood pressure levels.

We retrieved seven trials with morbidity and mortality outcomes (Table 2) [67–88]. Most included patients were older than 50 years with risk factors for cardiovascular disease, followed for 3–5 years, with cardiovascular events and mortality as main outcome measures. The Jadad scores ranged from 1 to 5 (Table 2). An average of three drugs was needed in an add-on strategy to reach blood pressure goals as defined in the trials. The majority of African descent participants (50–70 %) reached blood pressure control, but 95 % needed combination therapy. In line with the blood pressure lowering efficacy of monotherapy, more patients on calcium blocker-based treatment reached goal blood pressure, while there was a reduced blood pressure lowering response in treatments based on initial monotherapy with angiotensin II receptor blockers or ACE inhibitors [82, 83, 86].

There was no statistical difference between the different treatment arms in primary morbidity and mortality outcomes (Table 2). The main side effects of long-term therapy were newly developed diabetes (diuretics > calcium blockers > ACE inhibitors), and a significantly greater occurrence of cough and angioedema with ACE inhibitors, 72 per 10,000 (0.72 %), vs diuretics (0.04 %), and calcium blockers (0.06 %) for African ethnicity patients in ALLHAT [17, 86].

In the SHEP study, the overall effect of diuretics on the primary outcome stroke in African ethnicity patients was not significantly different from placebo. In subgroup analysis, stroke risk reduced in women of African ethnicity (relative risk 0.98 [CI 0.39; 2.44]) [69]. However, treatment did reduce cardiovascular events as a secondary outcome (hazard ratio for all cardiovascular events, 0.50 [CI 0.32; 0.78] (unpublished results, SHEP trial investigators).

Furthermore, in the ACCOMPLISH trial, there was no significant difference in African ethnicity patients between the two treatment strategies in retarding the rate of progression of kidney disease, in contrast to patients of other ethnicities where amldipine/benazepril-based therapy was more effective than hydrochlorothiazide/benazepril [84].

Although ACE inhibitor-based treatment yielded better clinical outcomes in kidney disease in the AASK trial [75], there was no difference in prevention of cardiovascular events by drug type [81], while the results of the ALLHAT trial indicates that cardiovascular morbidity outcomes were worse with treatments based on inhibitors of the renin angiotensin system [86]. The use of losinpril initiated treatment vs chlorthalidone in patients of African ethnicity was associated with a relative greater risk of morbidity: combined CHD (1.15 [1.02; 1.30]), combined CVD (1.19 [1.09; 1.30]), stroke 1.40 [1.17; 1.68], angina 1.24 [1.07; 1.44]. Heart failure risk was lower with chlorthalidone [86]. No data were provided for lisinopril vs amldipine.

In line with these findings with ACE inhibitors, the LIFE study showed that losartan-initiated therapy was superior to atenolol-initiated therapy in reducing stroke risk in hypertensive patients of European descent. However, among patients of African descent, losartan-initiated treatment was associated with a nearly significant increase in stroke events compared with atenolol unadjusted hazard ratio, 1.99 [1.00; 3.98] [85], similar to the findings of the primary outcome, a composite outcome including stroke [17, 73]. In addition, the risk for sudden death was 97 % higher in patients of African descent in the LIFE trial, with, at this relatively small sample size (n = 533) a trend towards increased risk with losartan [87]. These data indicate that therapy initiated with blockers of the renin-angiotensin-system is associated with a greater cardiovascular morbidity and mortality in patients of African ethnicity.

We defined subgroups based on gender and based on geographical location for morbidity and mortality outcomes. However, morbidity and mortality trials were conducted in the USA only or included only a very small number of non-USA patients (Table 2). The SHEP trial’s outcome for men and women is discussed above, with diuretics not significantly different from placebo in preventing stroke in African ethnicity men. In ALLHAT, men of African descent had the highest absolute stroke risk (mean 6 year rate/100 patients 7.73, 5.90, 5.81, and 5.90, in African ethnicity men, women, and white men, women respectively) and the highest stroke risk with lisinopril of all sex-ethnic groups (6 year rate/100 patients for lisinopril 9.41, 7.25, 5.32, and 5.59, respectively) [88]. Furthermore, pharmacogenetics outcomes differed by gender in the AASK trial, only women randomized to a usual blood pressure goal (mean arterial pressure 102–107 mmHg), and with an A allele at CYP3A4 A392G, were more likely to reach a target MAP of 107 mmHg [adjusted hazard ratio of AA/AG compared to GG 3.41 (95 % CI 1.20–9.64; P = 0.02)]. Among participants randomized to a lower MAP goal, men and women with the C allele at CYP3A4 T16090C were more likely to reach the target MAP of 107 mmHg [adjusted hazard ratio 2.04 (95 % CI 1.17–3.56; P = 0.01)]. In addition, the polymorphisms Arg655Leu, Ala142Val, and Ala486Val of the G protein-coupled receptor kinase gene, GRK4, were studied in the
AASK Study. Only in men randomized to the usual blood pressure goal (mean arterial pressure 102–107 mmHg), the adjusted “hazard” ratio to reach the goal blood pressure with metoprolol was 1.54 (95% CI 1.11–2.44; P < 0.01) with Ala142Val. There was no association between GRK4 polymorphisms and blood pressure response to metoprolol in women [16].

Compliance data by ethnicity were only available for the AASK study. Based on self-reported data and pill counts, 23% of the patients had at least one noncompliant event, non-adherence events (%) per patient year respectively were 7.7, 6.6, and 7.1 for metoprolol, ramipril and amlodipine [74–76].

As approaches to the management of cardiovascular disease risk need to integrate assessment and treatment of several risk factors, we describe the outcome of the lipid lowering treatment arm of the ALLHAT trial (ALLHAT-LLT) [89]. Patients of African ethnicity have been under-represented in prior trials addressing the effects of cholesterol lowering. Participants treated for hypertension in ALLHAT were eligible for inclusion in ALLHAT-LLT when fasting LDL-C levels were 120–189 mg/dL (3.1–4.9 mmol/L) or 100–129 mg/dL (2.6–3.3 mmol/L) respectively for those with and without known coronary heart disease. The primary outcome was all-cause mortality in patients randomized to pravastatin 20–40 mg vs usual care (respectively n = 1769 vs n = 1722 African ethnicity patients). Vigorous cholesterol lowering therapy was discouraged in the usual care group, therefore the majority of these patients did not receive lipid lowering drugs (90% in the second year to 72% in the sixth year of the trial). There was no difference in the primary outcome of all-cause mortality between pravastatin and usual care (RR for African ethnicity patients 1.01 [0.85–1.19]). In other outcomes, the relative risk for atherosclerotic coronary heart disease events with pravastatin was lower in patients of African descent than in other patients (RR 0.73 [0.58–0.92] vs 1.02 [0.81–1.28]; P = 0.03). However, there was a significantly greater stroke risk with pravastatin in patients of African descent (RR 1.12 vs 0.74 in other patients, confidence intervals not reported; P = 0.03). As a result, there was no significant effect of pravastatin treatment on combined cardiovascular disease outcomes in hypertensive patients of African ethnicity [89].

Patients of South Asian ethnicity

With electronic searches (November 2015) we retrieved 1578 papers. We additionally retrieved three trials with hand search, which were not eligible for inclusion. Sixteen randomized controlled trials were included, with blood pressure as the main outcome. Only one trial was placebo controlled, other trials assessed monotherapy with a drug from one drug class vs a drug from another class. We did not include trials that only compared drugs within one antihypertensive drug class. The 16 included trials (Fig. 3; Table 3) were 4 weeks to 9 months duration (median 8 weeks), containing original data of 6 classes of antihypertensive drugs in 1719 South Asian hypertensive patients without a history of, or current cardiovascular events (n = 37 diabetics) [55, 90–104].

Blood pressure at inclusion was generally between 140 and 180 mmHg systolic, and 90 to 110 mmHg diastolic. Most trials were conducted in India. The methodological quality of the trials was less than in the African patients, with the Jadad scores between 1 and 4 (median 2). No trial had a Jadad score of 5, and only 2 were double blinded. Most trials reported side effects and drop outs, but intention-to-treat analysis was used in only one (Table 3).

There were no significant differences between drug classes in blood pressure-lowering efficacy, as analysed per comparison presented in the trial data [35], (data not shown). Calculation of the blood pressure lowering effect per drug class was hampered by the limited data and heterogeneity that could not be well accounted for (partly due the small number of trials). However, South Asians ethnicity patients represent a population subgroup where the average effect is of clinical relevance. Therefore, we allowed for heterogeneity in an a posteriori analysis, and used the random effects model to calculate the inverse variance-weighted mean blood pressure lowering effect of the different drug classes (Table 4) [35].

Other effects described included that lisinopril reduced micro-albuminuria (−33 vs −10% in amlodipine) [95], while diuretics and beta-adrenergic blockers were reported to have the well-known metabolic side effects on lipid and glucose metabolism. Non-diuretic, non-beta-adrenergic

Fig. 2 Effect of different antihypertensive drugs on blood pressure in patients of African ethnicity. a. Systolic blood pressure. b. Diastolic blood pressure. a, b Our previous review [17] was updated (November 2015). Except for two nebivolol studies [46, 53], no new trials with single drugs vs placebo and blood pressure outcomes were retrieved. Random, random-effects model. Results are reported as weighted mean differences in reduction of systolic and diastolic blood pressure (mmHg) from baseline to endpoint with the use of different antihypertensive drugs compared to placebo. Squares are weighted mean differences in reduction of SBP/DBP (mmHg). The size of the squares represents study weight, and horizontal lines represent 95% CIs. Arrowheads depict data outside the scale. When a study provided only the placebo-drug difference, we entered a “nil” for placebo results. Results for Materson and colleagues’ study and Weir and colleagues’ study are weighted means of older and younger people and patients receiving a high and a low-salt diet, respectively. Black diamonds are pooled estimates. Results for calcium-channel blockers were not pooled because the size of the effect was heterogeneous. ABC Association of Black Cardiologists, TAIM Trial of Antihypertensive Interventions and Management, TOMHS Treatment of Mild Hypertension Study, TROPHY Treatment in Obese Patients with Hypertension [36–66].
### a. Systolic blood pressure

| Study                  | Treatment | Placebo | WMD (95% CI Random) | Weight | WMD (95% CI Random) |
|------------------------|-----------|---------|---------------------|--------|--------------------|
| **Comparison: 01 Calcium channel blockers**                        |           |         |                     |        |                    |
| Fadayomi et al. (40)   | 15        | 15      | -2.7 (17.4)         | 17.7   | -58.30 [-69.57; 47.03] |
| Materson et al. (47)   | 90        | 88      | -2.8 (10.5)         | 21.8   | 12.80 [-15.60; -10.00] |
| Moser et al. (50)      | 35        | 33      | 1.9 (11.1)          | 21.0   | 11.40 [-16.68; -6.12] |
| TOMHS (60)             | 16        | 17      | 1.4 (11.1)          | 20.5   | -7.90 [-14.20; -1.60] |
| Weir et al. (65)       | 24        | 23      | 1.8 (13.2)          | 19.1   | 12.10 [-21.01; -3.19] |
| **Total**              | 121       | 120     |                     | 100.0  | -7.43 [-11.64; -3.22] |

Test for heterogeneity: chi square=64.67 df=4  p<0.00001  I²=94%

**Comparison: 02 Diuretics**

| Study                  | Treatment | Placebo | WMD (95% CI Random) | Weight | WMD (95% CI Random) |
|------------------------|-----------|---------|---------------------|--------|--------------------|
| Moser et al. (49)      | 11        | 7       | -13.7 (12.6)        | 20.1   | -9.80 [-15.09; -4.51] |
| Flack et al. (43)      | 107       | 100     | -1.6 (19.7)         | 10.7   | 0.00 [-7.73; 7.73] |
| Venter et al. (63)     | 36        | 37      | -7.1 (13.2)         | 1.7    | 20.00 [-37.13; 2.87] |
| **Total**              | 204       | 204     |                     | 100.0  | 0.00 [-5.50; 5.50] |

Test for overall effect: z=7.34  p<0.00001

**Comparison: 03 Centrally acting agents**

| Study                  | Treatment | Placebo | WMD (95% CI Random) | Weight | WMD (95% CI Random) |
|------------------------|-----------|---------|---------------------|--------|--------------------|
| Materson et al. (47)   | 84        | 88      | -1.8 (10.5)         | 100.0  | -13.20 [-16.72; -9.68] |
| **Total**              | 84        | 88      |                     | 100.0  | -13.20 [-16.72; -9.68] |

Test for overall effect: z=7.34  p<0.00001

**Comparison: 04 Angiotensin converting enzyme inhibitors**

| Study                  | Treatment | Placebo | WMD (95% CI Random) | Weight | WMD (95% CI Random) |
|------------------------|-----------|---------|---------------------|--------|--------------------|
| Materson et al. (47)   | 92        | 88      | -1.8 (10.5)         | 39.7   | -5.70 [-8.91; -3.52] |
| MOSR (49)              | 11        | 7       | 0.4 (12.6)          | 4.8    | -14.10 [-26.04; -2.16] |
| TROPHY (61)            | 22        | 19      | -4.2 (12.6)         | 20.1   | -9.80 [-15.09; -4.51] |
| Venter et al. (63)     | 7         | 6       | 0.9 (19.6)          | 10.7   | 1.60 [-5.50; 2.57] |
| **Total**              | 121       | 120     |                     | 100.0  | -1.60 [-5.50; 2.57] |

Test for heterogeneity: chi square=2.94 df=2  p=0.32  I²=32%

Test for overall effect: z=3.46  p<0.00005

**Comparison: 05 Alpha-adrenergic blockers**

| Study                  | Treatment | Placebo | WMD (95% CI Random) | Weight | WMD (95% CI Random) |
|------------------------|-----------|---------|---------------------|--------|--------------------|
| Materson et al. (47)   | 91        | 88      | -1.8 (10.5)         | 60.1   | -8.90 [-12.28; -5.52] |
| TOMHS (60)             | 24        | 47      | 0.0 (10.8)          | 38.3   | -4.40 [-9.71; 0.91] |
| Venter et al. (63)     | 5         | 6       | 9.0 (19.6)          | 7.3    | -24.00 [-36.38; 1.08] |
| **Total**              | 121       | 120     |                     | 100.0  | -3.63 [-5.47; -1.78] |

Test for heterogeneity: chi square=2.16 df=3  p=0.54  I²=0%

Test for overall effect: z=3.86  p<0.00001

**Comparison: 07 Beta-adrenergic blockers**

| Study                  | Treatment | Placebo | WMD (95% CI Random) | Weight | WMD (95% CI Random) |
|------------------------|-----------|---------|---------------------|--------|--------------------|
| Flack et al. (43)      | 177       | 150     | -1.3 (14.9)         | 30.0   | -5.10 [-8.46; -1.74] |
| Conlin et al. (37)     | 18        | 18      | 2.3 (8.1)           | 12.1   | -2.00 [-7.29; 3.29] |
| Flack et al. (43)      | 190       | 184     | -2.3 (14.9)         | 37.1   | -4.10 [-7.12; -1.08] |
| **Total**              | 476       | 457     |                     | 100.0  | -3.63 [-5.47; -1.78] |

Test for heterogeneity: chi square=2.16 df=3  p=0.54  I²=0%

Test for overall effect: z=3.86  p<0.00001
### b. Diastolic blood pressure

| Study                          | Treatment n | Placebo n | WMD (95% CI Random) | Weight % | WMD (95% CI Random) |
|-------------------------------|-------------|-----------|---------------------|----------|---------------------|
| **Comparison: 01 Calcium channel blockers** | 15 | 15 | 12.3 | 14.3 | 33.0 | 25.4 |
| Fadysami et al. (40)         | 34 | 12 | -4.4 (6.4) | 15.8 | 10.10 [11.81;8.39] |
| Fiddes et al. (41)           | 90 | 88 | 4.0 | 15.8 | 10.10 [11.81;8.39] |
| Materson et al. (47)         | 25 | 24 | 1.0 | 15.8 | 10.10 [11.81;8.39] |
| Moser et al. (50)            | 35 | 33 | 2.2 (6.4) | 15.1 | 7.50 [4.04;10.54] |
| Opie et al. (51)             | 14 | 17 | -2.3 (6.4) | 14.0 | -7.80 [2.57;3.27] |
| TOMHS (60)                   | 16 | 16 | -4.5 (6.5) | 14.0 | -7.80 [2.57;3.27] |
| Weir et al. (65)             | 34 | 47 | 0.0 (6.2) | 14.8 | -3.70 [1.72;0.18] |
| Venter et al. (63)           | 10 | 8 | -2.0 (7.2) | 13.7 | -9.40 [1.24;6.54] |
| **Total**                    | 212 | 239 | 100.0 | -3.84 [1.85;5.48] | 100.0 | -3.84 [1.85;5.48] |
| Test for heterogeneity chi square=71.67 df=6 p<0.0001 | 45% |
| **Comparison: 02 Diuretics** | 19 | 19 | 10.0 | 10.0 | -6.00 [11.83;1.17] |
| Dean et al. (38)              | 92 | 92 | 9.9 | 20.9 | -6.0 [8.53;6.67] |
| Fiddes et al. (41)           | 21 | 21 | 9.9 | 20.9 | -6.0 [8.53;6.67] |
| Materson et al. (47)         | 24 | 24 | 10.0 | 5.9 | -18.0 [25.02;10.98] |
| Seedat (54)                  | 24 | 24 | 4.0 | 16.2 | -5.50 [8.43;1.57] |
| Stein et al. (56)            | 19 | 19 | 8.0 | 11.0 | -9.5 [13.96;5.04] |
| TOMHS (60)                   | 27 | 27 | 11.0 | 4.2 | -11.0 [19.67;3.23] |
| TROPHY (61)                  | 10 | 10 | 16.6 | -5.00 [7.95;2.05] |
| Venter et al. (63)           | 10 | 10 | 16.6 | -5.00 [7.95;2.05] |
| **Total**                    | 267 | 264 | 100.0 | -3.84 [1.85;5.48] | 100.0 | -3.84 [1.85;5.48] |
| Test for heterogeneity chi square=16.44 df=9 p=0.0001 | 45% |
| **Comparison: 03 Centrally acting agents** | 92 | 88 | 27.9 | 7.3 | 3.80 [3.21;10.81] |
| Materson et al. (47)         | 92 | 92 | 9.9 | 20.9 | -6.0 [8.53;6.67] |
| Fiddes et al. (41)           | 21 | 21 | 9.9 | 20.9 | -6.0 [8.53;6.67] |
| Materson et al. (47)         | 25 | 25 | 10.0 | 13.6 | -5.70 [10.24;1.16] |
| Sevadat (54)                 | 22 | 22 | 7.3 | 3.4 | 6.84 [14.89] |
| Stein et al. (56)            | 28 | 28 | 7.1 | 19.3 | -6.20 [9.52;2.88] |
| TOMHS (60)                   | 27 | 27 | 7.1 | 19.3 | -6.20 [9.52;2.88] |
| TROPHY (61)                  | 7 | 7 | 19.3 | -6.20 [9.52;2.88] |
| Venter et al. (63)           | 36 | 36 | 100.0 | -3.35 [5.59;1.73] | 100.0 | -3.35 [5.59;1.73] |
| **Total**                    | 212 | 212 | 100.0 | -3.35 [5.59;1.73] | 100.0 | -3.35 [5.59;1.73] |
| Test for heterogeneity chi square=10.79 df=6 p=0.0001 | 44% |
| **Comparison: 05 Alpha-adrenergic blockers** | 92 | 88 | 52.6 | 41.0 | -1.00 [4.15;2.15] |
| Materson et al. (47)         | 92 | 92 | 9.9 | 25.6 | -5.10 [7.08;3.12] |
| TomHS (60)                   | 25 | 25 | 41.0 | 6.6 | -1.00 [4.15;2.15] |
| Venter et al. (64)           | 7 | 7 | 6.6 | 6.6 | -1.00 [4.15;2.15] |
| **Total**                    | 121 | 121 | 100.0 | -3.35 [5.69;0.01] | 100.0 | -3.35 [5.69;0.01] |
| Test for heterogeneity chi square=4.67 df=2 p=0.0095 | 57% |
| **Comparison: 06 Angiotensin II receptor blockers** | 151 | 145 | 32.9 | 9.4 | -0.50 [4.35;3.35] |
| AABC (36)                    | 18 | 18 | 9.4 | 32.9 | -2.40 [4.46;0.34] |
| Conlin et al. (37)           | 190 | 184 | 37.7 | 20.0 | -1.20 [3.84;1.44] |
| Flack et al. (42)            | 117 | 110 | 20.0 | 100.0 | -2.09 [3.28;0.91] |
| Flack et al. (43)            | 476 | 457 | 100.0 | -2.09 [3.28;0.91] | 100.0 | -2.09 [3.28;0.91] |
| **Total**                    | 476 | 457 | 100.0 | -2.09 [3.28;0.91] | 100.0 | -2.09 [3.28;0.91] |
| Test for heterogeneity chi square=4.67 df=3 p=0.0027 | 0% |
| **Comparison: 07 Beta-adrenergic blockers** | 26 | 15 | 5.7 | 2.7 | -0.20 [-4.75;7.05] |
| Frishman et al. (44)         | 106 | 44 | 10.7 | 40.0 | -6.50 [-8.40;4.60] |
| Lewin et al. (46)            | 81 | 44 | 10.7 | 40.0 | -6.50 [-8.40;4.60] |
| Materson et al. (47)         | 81 | 44 | 10.7 | 40.0 | -6.50 [-8.40;4.60] |
| Saiklo et al. (52)           | 26 | 16 | 3.8 | 14.2 | -4.70 [-7.89;1.51] |
| Saunders et al. (53)         | 24 | 16 | 2.8 | 14.2 | -4.70 [-7.89;1.51] |
| Sevadat (54)                 | 24 | 24 | 16.6 | 2.8 | -4.0 [1.15;2.73] |
| TOMHS (60)                   | 24 | 24 | 16.6 | 2.8 | -4.0 [1.15;2.73] |
| Venter et al. (62)           | 19 | 24 | 3.5 | 16.6 | -5.50 [-7.95;2.05] |
| **Total**                    | 385 | 319 | 100.0 | -5.30 [-6.58;4.18] | 100.0 | -5.30 [-6.58;4.18] |
| Test for heterogeneity chi square=6.83 df=6 p=0.0660 | 0% |

Fig. 2 continued
| References       | Participants of African ethnicity | Drug intervention vs placebo | Treatment duration | Outcome measure (BP) | Analysis of results | Adverse effects | Jadad score | RA | MR | DB | MB | DO | Total |
|------------------|----------------------------------|------------------------------|--------------------|----------------------|----------------------|-------------------|--------------|-----------------|-----------------|----------------|----------------|----------------|----------------|----------------|
| ABC [36]         | 304 USA Mean 52                  | Candesartan cilexetil 32     | 8 w                | Cont./dichot.        | ITT                  | Reported          | 1 – 1 1 1 1 4 |                 |
| Conlin et al. [37] | 18b USA Mean 52                  | Losartan 50                  | 4 w                | Cont.                | ITT                  | ND               | 1 – 1 1 1 4 |                 |
| Dean et al. [38]  | 60 RSA Adults                    | Hydrochlorothiazide 50       | 2 w                | Cont.                | PP                   | ND               | 1 – 1 – 3    |                 |
| Drayer et al. [39] | 58b USA Mean 53                  | Captopril 200                | 8 w                | Dichot.              | PP                   | ND               | 1 – 1 – 3    |                 |
| Fadayomi et al. [40] | 32 Nigeria Mean 48                | Nifedipine 40                | 6 w                | Cont./dichot.        | PP                   | Reported          | 1 – 1 1 3   |                 |
| Fiddes et al. [41] | 46 USA ≥55 DP                   | Diltiazem XR 480             | 8 w                | Cont.                | ITT                  | ND               | 1 – 1 – 2    |                 |
| Flack et al. [42] | 381 USA Mean 50                  | Losartan 150                 | 12 w               | Cont./dichot.        | ITT                  | Reported          | 1 – 1 1 3   |                 |
| Flack et al. [43] | 233b USA/RSA Mean 52             | Losartan 50–100              | 16 w               | Cont.                | ITT                  | ND               | 1 – 1 1 3   |                 |
| Frishman et al. [44] | 62b USA ≥21 DP                   | Hydrochlorothiazide 25       | 4 w                | Cont./dichot.        | ITT                  | ND               | 1 – 1 – 2    |                 |
| Humphreys et al. [45] | 18 Jamaica 46–63 DP              | Bisoprolol 5                 | 4 w                | Cont./dichot.        | ITT                  | Reported          | 1 1 1 1 4 |                 |
| Lewin et al. [46] | 152 USA Mean 51                  | Propanolol 360               | 2 m                | Cont./dichot.        | ITT                  | Reported          | 1 1 1 1 5   |                 |
| Materson et al. [47, 48] | 621 USA Mean 58                  | Diltiazem 360 Hydrochlorothiazide 50 | 8 w/1 y | Cont./dichot.        | ITT                  | ND               | 1 – 1 1 3   |                 |
| Moser et al. [49] | 20 Bahamas 32–60                 | Captopril 450                | 4 w                | Cont./dichot.        | PP                   | Reported          | 1 – 1 – 2    |                 |
| Moser et al. [50] | 77 USA 26–70 DP                  | Nifedipine 40                | 5 w                | Cont./dichot.        | PP                   | ND               | 1 – 1 1 3   |                 |
| Opie et al. [51]  | 31b RSA 18–75 DP                 | Nisoldipine 30               | 6 w                | Cont.                | ITT                  | ND               | 1 – 1 1 3   |                 |
| Salako et al. [52] | 20 Nigeria 37–60 DP              | Alpenol 400                  | 8 w                | Cont.                | PP                   | Reported          | 1 – 1 1 4   |                 |
| Saunders [53]     | 301 USA Mean 51                  | Nebivolol 40 mg              | 12 w               | Cont.                | ITT                  | Reported          | 1 – 1 1 3   |                 |
| References          | Participants of African ethnicity | Drug intervention vs placebo | Treatment duration | Outcome measure (BP) | Analysis of results | Adverse effects | Jadad score |
|---------------------|----------------------------------|-------------------------------|--------------------|----------------------|---------------------|-----------------|-------------|
| Seedat [54]         | 24 RSA Adults                    | DBP 100–115                   | 4 w                | Cont.                | ITT                 | Reported        | 1 – 1 – 1 – 1 – 3 |
| Seedat [55]         | 9 RSA Mean 44                    | DBP ≥110                      | 4 w                | Cont./dichot.        | ITT                 | ND              | 1 1 1 1 4 |
| Stein et al. [56]   | 25 Zimbabwe <70                  | DBP 96–114                    | 6 w                | Cont./dichot.        | PP                  | ND              | 1 – 1 – 1 – 3 |
| TAIM [57, 58]       | 98 USA Mean 46                   | DBP 90–100                    | 6 m                | Cont.                | ITT                 | ND              | 1 1 1 1 4 |
| TOMHS [59, 60]      | 177 USA Mean 54                  | DBP 90–99                     | 1 y                | Cont.                | PP                  | Reported for women only | 1 – 1 1 – 3 |
| TROPHY [61]         | 68 USA 21–75                     | DBP 90–109                    | 12 w               | Cont.                | PP                  | ND              | 1 1 1 1 3 |
| Venter et al. [62]  | 50 RSA 25–65                     | DBP 95–115                    | 12 w               | Cont./dichot.        | PP                  | Reported        | 1 – 1 1 1 4 |
| Venter et al. [63]  | 15 RSA 25–65                     | DBP 95–115                    | 12 w               | Cont.                | PP                  | Reported        | 1 – – – 1 2 |
| Venter et al. [64]  | 29 RSA 21–65                     | DBP 95–115                    | 10 w               | Cont./dichot.        | PP                  | Reported        | 1 – 1 1 1 4 |
| Weir et al. [65]    | 56 USA Mean 52                   | DBP 95–115                    | 4 w                | Cont.                | PP                  | ND              | 1 1 1 1 – 4 |
| Weir et al. [66]    | 96 USA Mean 54                   | DBP 95–114                    | 6 w                | Cont.                | ITT                 | Reported        | 1 – 1 – 1 3 |

ABC Association of Black Cardiologists, N number of African ethnicity patients randomized, or evaluated in this review; USA United States of America, RSA Republic of South Africa, (D)BP diastolic blood pressure, mg milligram, w weeks, m months, y years, Cont./dichot. blood pressure reported as continuous or dichotomous outcome, ITT intention-to-treat, PP per protocol analysis, ND no data reported for African ethnicity patients, RA randomization, MR method of randomization, DB double blind, MB method of blinding, DO dropouts in African ethnicity patients, TAIM Trial of Antihypertensive Interventions and Management, TOMHS Treatment of Mild Hypertension Study, TROPHY Treatment in Obese Patients with Hypertension

a Highest daily dose
b Number of African ethnicity patients evaluated in this review
c Cross-over trial
d BP reported as continuous/dichotomous outcome
e Other drugs added in 12.5% of participants
f Second drug added in 9.2% of participants; plus life style interventions
g Obese patients
h Salt sensitive patients
i Plus high/low salt diet
j Weight sensitive patients
### Table 2: Trials with morbidity and mortality outcomes in African ethnicity patients

| Study       | N (%) | Country | Inclusion criteria | Treatment arms\(^a\) | Primary endpoint | Jadad score\(^b\) | Follow up (years) | Primary outcome |
|-------------|-------|---------|--------------------|----------------------|------------------|------------------|------------------|-----------------|
| SHEP        | 657 (14) | USA | >60 ISH | Chlorothalidone Placebo | Fatal/non-fatal stroke | 1 – 1 1 1 – | 3 | 4.5 | NS |
| LIFE        | 533 (6)  | 7 countries\(^c\) | 55–80 y LVH | Losartan Atenolol | MI, stroke, CVM | 1 1 1 1 | – | 4 | NS |
| AASK        | 1094 (100) | USA | 18–70 y GFR 20-65\(^d\) | Ramipril Metoprolol Amlodipine | GFR (usual vs low BP goals) | 1 1 1 1 | 1 | 5 | 4.1 | NS |
| ALLHAT      | 15,094 (35) | USA | ≥55 y CHD risk | Lisinopril Amlodipine Chlorthalidone Doxazosin | MI + CHD death | 1 1 1 1 | | 5 | 4.9 | NS |
| VALUE       | 639 (4) | 31 countries\(^e\) | ≥50 y CVD/risk | Valsartan Amlodipine | Time to first cardiac event | 1 1 1 1 | | | 4 | 4.2 | NS |
| INVEST      | 3029 (13) | 14 countries\(^e\) | ≥50 y CAD | Atenolol\(^f\) Verapamil | Death (ACM), MI, or stroke | 1 | – | – | | | 2.9 | NS |
| ACCOMPLISH  | 1414 (17) | 5 countries\(^e\) | ≥55 y TOD | Benazepril/HCT Benazepril/ Amlodipine | CVD, CVM | 1 | – | – | | | 3.0 | NS |

---

ISH isolated systolic hypertension, LVH left ventricular hypertrophy, GFR glomerular filtration rate, CAD coronary artery disease, CHD coronary heart disease, CVD cardiovascular disease, CVM cardiovascular mortality, TOD target organ damage, HCT hydrochlorothiazide, BP blood pressure, MI myocardial infarction, ACM all-cause mortality, NS no significant difference, SHEP the Systolic Hypertension in the Elderly Program [67–69], LIFE the Losartan Intervention for Endpoint Reduction in Hypertension Study [70–73, 85, 87], AASK African American Study of Kidney Disease and Hypertension [74–76, 81], ALLHAT Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial [77–80, 86, 88], VALUE Valsartan Antihypertensive Long-term Use Evaluation trial [82], INVEST the International Verapamil-Trandolapril Study [83], ACCOMPLISH Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension trial [84]

\(^a\) Parallel treatment arms with initial monotherapy, except SHEP (vs placebo), and ACCOMPLISH (initial combination therapy)

\(^b\) Jadad score: RA randomization, MR method of randomization, DB double blind, MB method of blinding, DO dropouts in African ethnicity patients

\(^c\) 98 % of the African ethnicity patients were from the USA

\(^d\) mL/min/1.73 m²

\(^e\) Country of origin African-ethnicity patients not reported

\(^f\) Primary add-on drug trandolapril (verapamil arm) and HCT (atenolol)

\(^g\) African ethnicity patients were from the USA
blocking drugs had a better metabolic profile [97, 99, 101]. There were no separate data provided based on gender, and no trials with morbidity and mortality outcomes.

**Discussion**

The WHO Global Monitoring Framework has set a target of 25 % reduction in premature mortality from non-communicable diseases by 2025, including a 25 % reduction in the prevalence of hypertension [105]. Hypertension is the main cause of cardiovascular disease and death across populations worldwide [106], and if the targets are met, premature CVD deaths are projected to be reduced to 5.7 million as a result of a 26 % reduction for men and a 23 % reduction for women [107]. Globally, decreasing the prevalence of hypertension accounts for the largest risk reduction, followed by a reduction in tobacco smoking for men and obesity for women [107]. Since hypertension may differ in age of onset, severity, and response to treatment in different ethnic groups, the increasing ethnic diversity of the European population creates a need for adjusted guidelines to adequately reduce risk factor level in all ethnic groups.

Antihypertensive drugs are the first cardiovascular therapy for which there was wide recognition of
| References  | Participants of South-Asian ethnicity | Drug intervention | Treatment duration | Outcome measure (BP) | Analysis of results | Adverse effects | Jadad score<sup>a</sup> |
|-------------|---------------------------------------|-------------------|-------------------|---------------------|---------------------|-----------------|---------------------|
| Akat [90]   | 80 IND 18–65 ND | Telmisartan 40 Enalapril 10 | 12 w | Cont. | PP | Reported | 1 – – – – 1 |
| Ali [91]    | 163 IND Mean 52 DBP 95–115 | Losartan 50 Amlodipine 5 | 8 w | Cont. | PP | Reported | 1 – – – 1 2 |
| Bhatia [92] | 30 IND 35–65 DBP 90–115 | Enalapril 5 Felodipine 5 Prazosin 2 | 8 w | Cont. | Unclear | Reported | 1 – – – – 1 |
| Devi [93]   | 161 IND Mean 50 SBP 140–180 DBP 90–114 | Metoprolol 50 Amlodipine 5 | 8 w | Cont./dichot. | ITT | Reported | 1 – – – – 1 2 |
| Goyal [94]  | 62 IND Mean 62 SBP 140–179 DBP 90–109 | Telmisartan 80 Amlodipine 10 | 8 w | Cont./dichot. | PP | Reported | 1 – – – – 1 |
| Jalal [95]  | 120<sup>b</sup> IND 44–63 DBP 90–100 | Amlodipine 10 Lisinopril 10 | 8 w | Cont./dichot. | Unclear | Reported | 1 – – – – 1 |
| Jamali [96] | 80 PAK 20–70 ND | Candesartan 16 Atenolol 50 Prazosin 5 Atenolol 100 | 90 d | Cont. | PP | Reported | 1 – – – – 1 2 |
| Joglekar [97] | 122 IND 30–70 SBP 140–180 DBP 90–110 | Prazosin 5 Atenolol 20 | 4 w | Cont./dichot. | PP | Reported | 1 1 – – 1 3 |
| Misra [98]  | 110<sup>c</sup> IND 30–70 SBP 140–180 DBP 90–110 | Atenolol 20 | 8 w | Cont./dichot. | PP | Reported | 1 1 – – 1 3 |
| Nadeesha [99] | 120<sup>d</sup> IND Mean 45 ND | Amlodipine 5 | 8 w | Cont. | PP | ND | 1 – – – – 1 2 |
| Pareek [100] | 300 IND 22–81 SBP 140–159 DBP 90–99 | Atenolol 25 CTD 6.25 Amlodipine 2.5 | 4 w | Cont./dichot. | PP | Reported | 1 1 – – 1 3 |
| Satia [101] | 65<sup>e</sup> IND 45–70 DBP 90–110 | Atenolol100 Nifedipine 20 | 9 m | Cont./dichot. | Unclear | ND | 1 – – – – 1 |
| Seedat [55] | 11 RSA 33–61 DBP ≥110 | Debrisoquine 20 Mefruside 25 | 4 w<sup>6</sup> | Cont./dichot. | PP | Reported | 1 1 1 – 1 4 |
| Shobha [102] | 145 IND 18–65 DBP 95–110 | Losartan 50 Atenolol 5 | 8 w | Cont./dichot. | PP | Reported | 1 – 1 – 1 3 |
Table 3 continued

| References | Participants of South-Asian ethnicity | Drug intervention | Treatment duration | Outcome measure (BP) | Analysis of results | Adverse effects | Jadad score<sup>a</sup> |
|------------|----------------------------------------|-------------------|--------------------|----------------------|---------------------|----------------|--------------------------|
| Sumbria [<sup>103</sup> | 106<sup>f</sup> IND Mean 45 SBP ≥140 DBP ≥90 | Metoprolol 200 Telmisartan 160 | 6 m | Cont. PP | Reported | 1 1 – – 1 3 |
| Sundar [<sup>104</sup>] | 44 IND 35–60 ND | Nifedipine 40 Atenolol 100 Propranolol 80<sup>h</sup> Captopril 100 | 4 w<sup>g</sup> | Cont. PP | Reported | 1 – – – – 1 |

Total daily dose is the maximum dose used.

N number of patients randomized, IND India, PAK Pakistan, RSA Republic of South Africa, BP blood pressure, SBP systolic blood pressure at inclusion, DBP diastolic blood pressure at inclusion, ND no data, mg milligram, d day, w week, m month, HCT hydrochlorothiazide, CTD chlorthalidone, Cont./dichot. blood pressure as continuous/dichotomous outcome, ITT intention-to-treat, PP per protocol analysis

<sup>a</sup> Jadad score: RA randomization, MR method of randomization, DB double blind, MB method of blinding, DO dropouts

<sup>b</sup> All patients were diagnosed with primary hypertension and microalbuminuria (30–300 mg/24 h), with creatinine clearance >80 mL/min/1.73 m<sup>2</sup>

<sup>c</sup> All patients had an abnormal lipid spectrum

<sup>d</sup> Number of patients in each treatment arm unknown, equal distribution assumed

<sup>e</sup> 52 % of the patients had diabetes

<sup>g</sup> Cross-over trial

<sup>f</sup> In the metoprolol treatment arm, 3.6 % had diabetes at baseline vs telmisartan, 2 %

<sup>h</sup> Data of beta-adrenergic blockers were averaged in the comparison of drug class vs drug class [<sup>35</sup>]
differences in clinical efficacy related to ethno-geographical ancestry [16]. Patients of African descent as a group respond better to calcium blockers and diuretics, while the response to β-adrenergic blockade and inhibition of the angiotensin converting enzyme is attenuated [16, 17]. Currently, self-identified ethno-geographic ancestry is the best available predictor of this differential blood pressure lowering response to antihypertensive drugs [16]. As in African patients, South Asians also develop hypertension at an earlier age, with more end organ damage, but there are no known differences in the blood pressure lowering response to antihypertensive drugs, and despite the greater mortality, to our knowledge there are no trials in South Asians with morbidity and mortality outcomes.

The existing evidence provides ample evidence of higher risk of premature cardiovascular mortality in South Asian and African ancestry groups [3–22]. However, to better quantify this risk and develop more effective guidelines, we need to improve risk assessment, and use risk scores validated for ethnic minorities [108, 109]. To this end, we urgently need European morbidity and mortality outcome data for these ethnic groups, as these are likely to differ from the American and Canadian situation, where far higher treatment and control rates for hypertension are reached [18, 110]. Thus, the risk of premature mortality in South Asian and African ancestry groups in Europe is probably underestimated [5]. Although new approaches to estimate risk in these groups have been launched [108, 109], there is still a need for data to support these.

Also, we need data on whether lower thresholds to start treatment and lower therapeutic goal blood pressures need to be applied [111]. The Systolic Blood Pressure Intervention (SPRINT) trial indicates a lower cardiovascular morbidity and mortality within 3 years with a systolic goal blood pressure <120 vs <140 mmHg. However, this difference does not reach statistical significance in the subgroup of African ethnicity patients, with a relatively small sample size and a substantially lower mean age (−5 years) in this subgroup [111]. The International Society for Hypertension in Blacks [112] advises the initiation of treatment in patients of African ethnicity from 135 systolic or 85 mmHg diastolic blood pressure, and similar approaches have been suggested in South Asians [113].

The strength of this work is that we systematically review the available evidence of antihypertensive drug treatment with monotherapy for uncomplicated hypertension, and combination therapy for morbidity and mortality outcomes in hypertensive patients of African and South Asian ethnicity. The aggregated evidence should facilitate guideline development to reduce premature adverse outcomes in these high-risk population subgroups, but many questions remain. We are not well informed regarding the socio-economic circumstances of trial participants, which may have affected treatment failure [18]. Also, the trials are conducted in the USA, Africa and India mainly, and data on European ethnic populations are scarce. In addition, trials rarely report outcomes for men and women separately. Finally, there are no available quantitative data on antihypertensive therapy to reduce morbidity and mortality in South Asians, and newer, non-drug techniques for blood pressure lowering in therapy-resistant hypertension such as renal denervation are of unknown efficacy in South Asians, while in African ethnicity patients there was no significant difference with a sham procedure [114].

However, since there are ample effective drugs available, reducing hypertension and risk of end organ damage in these ethnic groups may predominantly involve different health management strategies. Public health approaches have been suggested to combat hypertension in all ethnic groups, with better models of screening, delivery of care

### Table 4

| Drug class          | Systolic BP, mean reduction [CI] | Target SBP (%) | Diastolic BP, mean reduction [CI] | Target DBP (%) |
|---------------------|----------------------------------|----------------|----------------------------------|----------------|
| Calcium blockers    | −19.08 [−22.75; −15.42]          | 52−88          | −10.81 [−11.58; −10.04]          | 46−82          |
| Diuretics           | −13.58 [−24.40; −2.76]           | ND             | −9.75 [−16.30; −3.19]            | 0*             |
| ACE-inhibitors      | −22.51 [−24.73; −20.29]          | ND             | −12.78 [−16.61; −8.95]           | 44             |
| Alpha-blockers      | −10.41 [−19.48; −1.34]           | 39−44          | −10.06 [−13.78; −6.35]           | 0−65*          |
| ATII-blockers       | −22.63 [−28.55; −16.70]          | 80             | −14.88 [−16.49; −13.27]          | 59−97          |
| Beta-blockers       | −21.11 [−26.44; −15.77]          | 76             | −13.95 [−16.67; −11.23]          | 74−77          |

Depicted are inverse-variance weighted means (CI 95 % confidence intervals) of blood pressure reduction (mmHg) per drug type, and range of target blood pressure achievement (%) in South Asian hypertensive patients. Evidence from randomized controlled trials of antihypertensive monotherapy (n = 16; [55, 90–104]). Target blood pressure (n = 9 trials) [55, 93–95, 97, 98, 100–102] was defined by authors, usually SBP <140 mmHg; DBP <90 mmHg

* Trials typically had an inclusion baseline DBP <115 mmHg (Table 3). In the only trial with baseline DBP >110, no patient reached diastolic treatment goal with diuretics or alpha blockers [55]. No data were retrieved on centrally acting agents. There was no significant difference in blood pressure lowering effect of different drug types, using comparisons as reported in the trials.
(nurse-based, door-step care), the use of a registry to treat and follow all hypertensives, and initial low dose combination therapy to increase compliance and blood pressure lowering efficacy, while reducing adverse effects [115, 116]. Hypertensive patients of African or South Asian descent should benefit from these more aggressive approaches.

In summary, hypertension in persons of African or South Asian ethnicity occurs more frequently, and is associated with more therapy failure and more severe and earlier end organ damage. European guidelines for cardiovascular risk management should take this high risk into account. Persons of African or South Asian ethnicity need to be screened at a younger age, and treatment should potentially start at lower thresholds with early use of combination therapy and intensive treatment monitoring to reduce the high premature mortality.

Acknowledgments None.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Statement of human and animal rights All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent Informed consent was not required for this retrospective study.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Eurostat (2015) http://ec.europa.eu/eurostat/statistics-explained/index.php/Migration_and_migrant_population_statistics/nl. Accessed 11 Nov 2015
2. Nichols M, Townsend N, Luengo-Fernandez R, Leal J, Gray A, Scarborough P, Rayner M (2012) European cardiovascular disease statistics 2012. Brussels, European Society of Cardiology, Sophia Antipolis, European Heart Network
3. Gu Q, Burt VL, Paulose-Ram R, Yoon S, Gillum RF (2008) High blood pressure and cardiovascular disease mortality risk among US adults: the third National Health and Nutrition Examination Survey mortality follow-up study. Ann Epidemiol 18:302–309
4. Martins D, Tareen N, Ogedegbe G, Pan D, Norris K (2008) The relative risk of cardiovascular death among racial and ethnic minorities with metabolic syndrome: data from the NHANES-II mortality follow-up. J Natl Med Assoc 100:565–571
5. Cappuccio FP, Oakeshott P, Strazzullo P, Perry SM (2002) Application of Framingham risk estimates to ethnic minorities in United Kingdom and implications for primary prevention of heart disease in general practice: cross sectional population based study. BMJ 325:1271
6. Brewster LM, Stronks K, van Montfrans G (2009) Lipid profile in a triethnic population in the Netherlands: the Sunset Study. J Hypertens 27:S324
7. Dekker LH, Nicolaou M, van der A DL, Busschers WB, Brewster LM, Snoijder MB, Stronks K, van Valkengoed IG (2013) Sex differences in the association between serum ferritin and fasting glucose in type 2 diabetes among South Asian Surinamese, African Surinamese, and ethnic Dutch: the population-based SUNSET study. Diabetes Care 36:965–971
8. Brewster LM, Mairuhr G, Bindraban NR, Koopmans RP, Clark JF, van Montfrans GA (2006) Creatine kinase activity is associated with blood pressure. Circulation 114:2034–2039
9. Karthikeyan G, Teo KK, Islam S, McQueen MJ, Pais P, Wang X, Sato H, Lang CC, Sithi-Amorn C, Pandey MR, Kazmi K, Sanderson JE, Yusuf S (2009) Lipid profile, plasma apolipoproteins, and risk of a first myocardial infarction among Asians: an analysis from the INTERHEART Study. J Am Coll Cardiol 53:244–253
10. Okin PM, Kjeldsen SE, Dahlöf B, Devereux RB (2011) Racial differences in incident heart failure during antihypertensive therapy. Circ Cardiovasc Qual Outcomes 4:157–164
11. Joshi P, Islam S, Pais P, Reddy S, Dorairaj P, Kazmi K, Pandey MR, Haque S, Mendis S, Rangarajan S, Yusuf S (2007) Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. JAMA 297:286–294
12. Jolly S, Vittinghoff E, Chattopadhyay A, Bibbins-Domingo K (2010) Higher cardiovascular disease prevalence and mortality among younger blacks compared to whites. Am J Med 123:811–818
13. Opie LH, Seedat YK (2005) Hypertension in sub-Saharan African populations. Circulation 112:3562–3568
14. Haan YC, van Montfrans GA, Brewster LM (2015) The high creatine kinase phenotype is hypertension- and obesity-prone. J Clin Hypertens 17:322
15. Eastwood SV, Tillin T, Chaturvedi N, Hughes AD (2015) Ethnic differences in associations between blood pressure and stroke in South Asian and European men. Hypertension 66:481–488
16. Brewster LM, Seedat YK (2013) Why do hypertensive patients of African ancestry respond better to calcium blockers and diuretics than to ACE inhibitors and β-adrenergic blockers? A systematic review. BMC Med 11:141
17. Brewster LM, van Montfrans GA, Kleijnen J (2004) Systematic review: antihypertensive drug therapy in black patients. Ann Intern Med 141:614–627
18. Oudman I, Kewalbansingh PV, van Valkengoed I, Zwinderman AH, Clark JF, van Montfrans GA, Brewster LM (2013) Creatine kinase is associated with failure of hypertension treatment. J Hypertens 31:1025–1031
19. Kramer H, Han C, Post W, Goff D, Diez-Roux A, Cooper R, Jinagouda S, Shea S (2004) Racial/ethnic differences in hypertension and hypertension treatment and control in the multi-ethnic study of atherosclerosis (MESA). Am J Hypertens 17:963–970
20. Kizer JR, Arnett DK, Bella JN, Paracans M, Rao DC, Province MA, Oberman A, Kitzman DW, Hopkins PN, Liu JE, Devereux RB (2004) Differences in left ventricular structure between black and white hypertensive adults: the Hypertension Genetic Epidemiology Network study. Hypertension 43:1182–1188
21. Spencer CG, Beeser DG, Lip GY (2004) Ethnic differences in left ventricular size and the prevalence of left ventricular hypertrophy among hypertensive patients vary with electrocardiographic criteria. J Hum Hypertens 18:631–636
22. Mohan V, Seedat YK, Pradeepa R (2013) The rising burden of diabetes and hypertension in southeast Asian and African regions: need for effective strategies for prevention and control in primary health care settings. Int J Hypertens 2013:409083
23. Parati G, Steptoe A (2004) Stress reduction and blood pressure control in hypertension: a role for transcendental meditation? J Hypertens 22:2057–2060
24. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER 3rd, Simons-Morton DG, Karanja N, Lin PH. DASH-Sodium Collaborative Research Group (2001) Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 344:3–10
25. Graudal N, Jürgens G (2015) The blood pressure sensitivity to changes in sodium intake is similar in Asians, Blacks and Whites. An analysis of 92 randomized controlled trials. Front Physiol 6:157
26. Chan Q, Stamler J, Elliott P (2015) Dietary factors and higher blood pressure in African-Americans. Curr Hypertens Rep 17:10
27. Jessani S, Hatcher J, Chaturvedi N, Jafar TH (2008) Effect of low vs. high dietary sodium on blood pressure levels in a normotensive Indo-Asian population. Am J Hypertens 21:1238–1244
28. Patki PS, Singh J, Gokhale SV, Bulakh PM, Shrotri DS, Patwardhan B (1990) Efficacy of potassium and magnesium in essential hypertension: a double-blind, placebo controlled, crossover study. BMJ 301:521–523
29. Subramanian H, Soudarssanane MB, Jayalakshmy R, Thirumalasekaran N, Jafar TH (2008) Non-pharmacological interventions in hypertension: a community-based cross-over randomized controlled trial. Indian J Community Med 36:191–196
30. Selvanurthy W, Sridharan K, Ray US, Tiwary RS, Hegde KS, Radhakrishnan U, Sinha KC (1998) A new physiological approach to control essential hypertension. Indian J Physiol Pharmacol 42:205–213
31. Graudal N, Jürgens G, Baslund B, Alderman MH (2014) Compared with usual sodium intake, low- and excessive-sodium diets are associated with increased mortality: a meta-analysis. Am J Hypertens 27:1129–1137
32. Kalogeropoulos AP, Georgiopoulou VV, Georgiopoulou VN, Browne R, Saadat SM, Seri NF, Cardone E, Baracchi E, Nittard D, D'Oro C, D'Amore M, D'Amelio G (2015) Dietary sodium content, mortality, and risk for cardiovascular events in older adults: the Health, Aging, and Body Composition (Health ABC) Study. JAMA Intern Med 175:410–419
33. US Department of Agriculture and US Department of Health and Human Services (2010) Dietary guidelines for Americans, 2010, 7th edn. US Government Printing Office, Washington
34. Park IU, Taylor AL (2007) Race and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: a systematic review. Ann Fam Med 5:444–452
35. Higgins JPT, Green S (2011) (eds) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration
36. Association of Black Cardiologists (ABC) Candesartan Study Group (2000) Evaluation of candesartan cilexetil in black patients with systemic hypertension: the ABC Trial. Heart Dis 2:392–399
37. Conlin PR, Erlinger TP, Bohannon A, Miller ER 3rd, Appel LJ, Svetkey LP, Moore TJ (2003) The DASH diet enhances the blood pressure response to losartan in hypertensive patients. Am J Hypertens 16:337–342
38. Dean G, Louw S, Hersch C, Kirsten HO, Brereton DN, Finnemore L, Dewar J (1971) A double-blind trial in hypertension comparing Baycaton (FBA 1500), hydrochlorothiazide and placebo. S Afr Med J 45:323
39. Drayer JJ, Weber MA (1983) Monotherapy of essential hypertension with a converting-enzyme inhibitor. Hypertension 5:108–113
40. Fadaway MO, Akinroye KK, Ajao RO, Awoyinka LA (1986) Monotherapy with nifedipine for essential hypertension in adult blacks. J Cardiovasc Pharmacol 8:466–469
41. Fiddes R, Heym H, Hilty W, Lewin AJ, Codispoti J, McNally C, Stokes A, Gilderman L (1994) Blood pressure control with diltiazem XR, a novel extended-release formulation of diltiazem HCl, in mature and elderly hypertensive patients. Clin Ther 16:209–221
42. Flack JM, Saunders E, Gradman A, Kraus WE, Lester FM, Pratt JH, Alderman M, Green S, Vargas R, Espenshade M, Ceesay P, Alexander J Jr, Goldberg A (2001) Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. Clin Ther 23:1193–1208
43. Flack JM, Oparil S, Pratt JH, Roniker B, Garthwaite S, Kleiman JH, Yang Y, Krause SL, Workman D, Saunders E (2003) Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 41:1148–1155
44. Frishman WH, Burris JF, Mroczek WJ, Weir MR, Alemayehu D, Simon JS, Chen SY, Bryzinski BS (1995) First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension. J Clin Pharmacol 35:182–188
45. Humphreys GS, Delvin DG (1968) Ineffectiveness of propranolol in hypertensive Jamaicans. Br Med J 2:601–603
46. Lewin A, Punzi H, Luo X, Stapff M (2013) Nebivolol monotherapy for patients with systolic stage II hypertension: results of a randomized, placebo-controlled trial. Clin Ther 35:142–152
47. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kocchar MS, Hamburger RJ, Fye C, Lakshman R, Gottdiener J, Ramirez EA, Henderson WG (1993) Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 328:914–921
48. Materson BJ, Reda DJ, Cushman WC (1995) Department of Veterans Affairs single-drug therapy of hypertension study. Revised figures and new data. Am J Hypertens 8:189–192
49. Moser M, Lunn J (1982) Responses to captopril and enalapril in moderate hypertension. J Cardiovasc Pharmacol 6(Suppl 7):S1085–S1089
50. Moser M, Lunn J, Nash DT, Burris JF, Winer N, Simon G, Vlahakis ND (1984) Nitrendipine in the treatment of mild to moderate hypertension. J Cardiovasc Pharmacol 6(Suppl 7):S1085–S1089
51. Opie LH, Muller FO, Myburgh DP, Rosendorff C, Sareli P, Slevin OA, Myburgh DP, Rosendorff C, Sareli P (1980) Trial of atenolol and chlorthalidone for hypertension in black South Africans. Br Med J 281:1241–1243
55. Seedat YK (1980) An evaluation of debrisoquine and mefruside in the treatment of hypertension in African and Indian patients. Curr Med Res Opin 7:68–72
56. Stein CM, Neill P, Kusemamuriro T (1997) Antihypertensive effects of low doses of hydrochlorothiazide in hypertensive black Zimbabweans. Int J Cardiol 37:231–235
57. Davis BR, Blafox MD, Hawkins CM, Langford HG, Oberman A, Swencionis C, Wassertheil-Smoller S, Wylie-Rosett J, Zimbaldi N (1989) Trial of antihypertensive interventions and management. Design, methods, and selected baseline results. Control Clin Trials 10:11–30
58. Wassertheil-Smoller S, Davis BR, Oberman AS, Blafox MD, Langford HG, Wylie-Rosett J, Hawkins M, Zimbaldi N (1991) The Taim Study: sex-race differences in effects of diet and drugs on cardiovascular risk. Cardiovasc Risk Factors 1:3–11
59. Neaton JD, Grimm RH Jr, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, Cutler JA, TOMHS Research Group (1993) Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA 270:713–724
60. Grimm RH, Grandits GA, Flack JM (1997) Are black and white hypertensives really different? ABC Digest Urban Cardiol 4:10–16
61. Reisin E, Weir MR, Falkner B, Hutchinson HG, Anzalone DA, Tuck ML, Treatment in Obese Patients with Hypertension (TROPHY) Study Group (1997) Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Hypertension 30:140–145
62. Venter CP, Joubert PH, Venter HL, Muntingh GL, du Plooy WJ (1990) Penbutolol in the treatment of mild to moderate essential hypertension in black South Africans. J Clin Pharmacol 30:533–537
63. Venter CP, Muntingh GL, Venter HL, du Plooy WJ (1991) The effect of xipamide on mild-moderate hypertension in black South Africans—results of a clinical trial. Med Sci Res 19:217–218
64. Venter CP, Venter HL, Muntingh GL (1991) The effect of enalapril and prazosin on mild to moderate hypertension in black South Africans. S Afr Med J 80:324–326
65. Weir MR, Chrysant SG, McCarron DA, Canossa-Terris M, Cohen JD, Gunter PA, Lebow AJ, Mennella RF, Kirkegaard LW, Hamilton JH, Weinberger MH, Weder AB (1998) Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives. Hypertension 31:1088–1096
66. Weir MR, Saunders E (1998) Renin status does not predict the antihypertensive response to angiotensin-converting enzyme inhibition in African-Americans. Trandolapril Multicenter Study Group. J Hum Hypertens 12:189–194
67. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group (1988) Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. J Clin Epidemiol 41:1197–1208
68. SHEP Cooperative Research Group (1991) Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 265:3255–3264
69. The Systolic Hypertension in the Elderly Program Cooperative Research Group (1993) Implications of the systolic hypertension in the elderly program. Hypertension 21:335–343
70. Dahlöf B, Devereux R, de Faire U, Fyhquist F, Hedner T, Isaksen H, Julius S, Kjeldsen S, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Ompvik P, Opaschowski P, Wedel H (1997) The Losartan Intervention for Endpoint reduction (LIFE) in hypertension study: rationale, design, and methods. Am J Hypertens 10:705–713
71. Okin PM, Devereux RB, Iern S, Kjeldsen SE, Julius S, Dahlöf B (2000) Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. Hypertension 36:766–773
72. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhquist F, Isaksen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Ompvik P, Opaschowski P, Wedel H, LIFE Study Group (2002) Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:995–1003
73. Julius S, Alderman MH, Beevers G, Dahlöf B, Devereux RB, Douglas JG, Edelman JM, Harris KE, Kjeldsen SE, Nesbitt S, Randall OS, Wright JT (2004) Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study. J Am Coll Cardiol 43:1047–1055
74. Gassman JJ, Greene T, Wright JT Jr, Agodoa L, Bakris G, Beck GJ, Douglas J, Jamerson K, Lewis J, Kuttner M, Randall OS, Wang SR (2003) Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). J Am Soc Nephrol 14:S154–S165
75. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, African American Study of Kidney Disease and Hypertension (AASK) Study Group (2001) Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 285:2719–2726
76. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, African American Study of Kidney Disease and Hypertension Study Group (2002) Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 288:2421–2431
77. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT Jr, Cushman WC, Grimm RH, LaRosa J, Whelton PK, Perry HM, Alderman MH, Ford CE, Oparil S, Francis C, Proschman M, Pressel S, Black HR, Hawkins CM (1996) Rationale and design for the AntiHypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Am Hypertens 9:342–360
78. Grimm RH Jr, Margolis KL, Papademetriou VV, Cushman WC, Ford CE, Bettencourt I, Alderman MH, Basile JN, Black HR, DeQuattro VV, Eckfeldt JH, Hawkins CM, Perry HM Jr, Proschan M (2001) Baseline characteristics of participants in the Anti-Hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Am Hypertens 24:367–379
79. ALLHAT Collaborative Research Group (2000) Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 283:1967–1975
80. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Reducing Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288:2981–2997
81. Norris K, Bourgoignie J, Gassman J, Hebert L, Middleton J, Phillips RA, Randall O, Rostand S, Sherer S, Toto RD, Wright JT Jr, Wang X, Greene T, Appel LJ, Lewis J, AASK Study Group (2006) Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. Am J Kidney Dis 48:739–751
82. Zanchetti A, Julius S, Kjeldsen S, McInnes GT, Hua T, Weber M, Laragh JH, Plat F, Battegay E, Calvo-Vargas C, Ciesielski A,
87. Okin PM, Kjeldsen SE, Julius S, Dahlof B, Devereux RB (2012) 
85. Kizer JR, Dahlof B, Kjeldsen SE, Julius S, Beevers G, De Faire 
95. Jalal S, Sofi FA, Abass SM, Alai MS, Bhat MA, Rather HA, 
94. Goyal J, Khan ZY, Upadhyaya P, Goyal B, Jain S (2014) 
92. Bhatia J, Mahajan P, Sikka M, Kalra OP (2001) Effect of var-
91. Ali G, Kamili MMA, Kumar M, Rashid S, Dhar S, Pandita VR, 
89. ALLHAT Officers and Coordinators for the ALLHAT Collab-
88. Yamal JM, Oparil S, Davis BR, Alderman MH, Calhoun DA, 
83. Jamerson K, Champion A, Zhou Q, Pepine C (2005) Verapamil-
81:568–576 
80. Akat PB, Bapat TR, Murthy MB, Karande VB, Burute SR (2002) 
89. (abstract P286) 
84. Weir MR, Bakris GL, Weber MA, Dahlof B, Devereux RB, 
Kjeldsen SE, Pitt B, Wright JT, Kelly RY, Hua TA, Hester RA, 
Velasquez E, Jamerson KA (2012) Renal outcomes in hyper-
tensive Black patients at high cardiovascular risk. Kidney Int 81:568–576 
85. Kizer JR, Dahlof B, Kjeldsen SE, Julius S, Beevers G, De Faire 
U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, 
Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, 
Wachtell K, Edelman JM, Snappin SM, Harris KE, Devereux RB (2005) Stroke reduction in hypertensive adults with cardiac 
hypertrophy randomized to losartan versus atenolol: the Losar-
tan Intervention for Endpoint reduction in hypertension study. 
Hypertension 45:46–52 
86. Wright JT Jr, Dunn JK, Cutler JA, Davis BR, Cushman WC, 
Ford CE, Haywood LJ, Leenen FHJ, Margolis KL, Papademetriou V, 
Probstfield JL, Whelton PK, Habib GB (2005) Outcomes in hypertensive black and nonblack patients treated with 
chlorthalidone, amlopidine, and lisinopril. JAMA 293:1595–1608 
87. Okin PM, Kjeldsen SE, Julius S, Dahlof B, Devereux RB (2012) 
Racial differences in sudden cardiac death among hypertensive 
patients during antihypertensive therapy: the LIFE study. Heart Rhythm 9:531–537 
88. Yamal JM, Oparil S, Davis BR, Alderman MH, Calhoun DA, 
Cushman WC, Fendley HF, Franklin SS, Habib GB, Pressel SL, 
Probstfield JL, Sastrasinh S (2014) Stroke outcomes among participants randomized to chlorthalidone, amlopidine or 
lisinopril in ALLHAT. J Am Soc Hypertens 8:808–819 
89. ALLHAT Officers and Coordinators for the ALLHAT Collabora-
87. Okin PM, Kjeldsen SE, Julius S, Dahlof B, Devereux RB (2012) 
Racial differences in sudden cardiac death among hypertensive 
patients during antihypertensive therapy: the LIFE study. Heart Rhythm 9:531–537 
88. Yamal JM, Oparil S, Davis BR, Alderman MH, Calhoun DA, 
Cushman WC, Fendley HF, Franklin SS, Habib GB, Pressel SL, 
Probstfield JL, Sastrasinh S (2014) Stroke outcomes among participants randomized to chlorthalidone, amlopidine or 
lisinopril in ALLHAT. J Am Soc Hypertens 8:808–819 
90. Akat PB, Bapat TR, Murthy MB, Karande VB, Burute SR (2010) Comparison of the efficacy and tolerability of telmisartan 
and enalapril in patients of mild to moderate essential hyper-
tension. Indian J Pharmacol 42:153–156 
91. Ali G, Kamili MMA, Kumar M, Rashid S, Dhar S, Pandita VR, 
Wadhwa MB (2001) Efficacy & tolerability of losartan com-
pared with amlopidine in the treatment of essential hypertension. 
JK Pract 8:140–142 
92. Bhatia J, Mahajan P, Sikka M, Kalra OP (2001) Effect of various 
antihypertensive drugs on plasma fibrinogen levels in 
patients with essential hypertension. Indian J Med Sci 55:491 
93. Devi P, Xavier D, Sigamani A, Pandey S, Thomas T, Murthy S, 
Sharma K, Bosco B, Mehta K, Joshi S, Gupta R, Singh G, Hureamath J, 
Dc S, Nambiar A, Puis P (2011) Effect of fixed dose combinations of 
metoprol and amlopidine in essential hypertension: mARA—a randomized controlled trial. Blood Press Suppl 25:5–12 
94. Goyal J, Khan ZY, Upadhyaya P, Goyal B, Jain S (2014) Comparative study of high dose mono-therapy of amlopidine or 
telmisartan, and their low dose combination in mild to moderate 
hypertension. J Clin Diagn Res 8:HC08–HC11 
95. Jalal S, Sofi FA, Abass SM, Alai MS, Bhat MA, Rather HA, 
Lone NA, Siddiqi MA (2010) Effect of amlopidine and lisinopril 
on microalbuminuria in patients with essential hypertension: a prospective study. Indian J Nephrol 20:15–20 
96. Jamali S, Mashori GR, Maher Z, Khan M (2008) Comparison of 
candesartan cilexetil and atenolol in essential hypertensive 
patients. Med Chan 14:28–31 
97. Joglekar SJ, Jaguste V, Nanivadekar AS (1998) Prazosin GITS 
vs atenolol in patients with hypertension and normal lipid pro-
file: a randomized, controlled multicenter study. Hyderabad 
Hypertension Study Group. J Assoc Physicians India Suppl 1:41–51 
98. Misra KP, Joglekar SJ, Mukherjee S, Nanivadekar AS (1998) 
Prazosin GITS vs sustained release nifedipine in patients with 
hypertension and abnormal lipid profile: a randomized, con-
trolled, multicenter study. Madras Hypertension Study Group. 
J Assoc Physicians India Suppl 1:30–40 
99. Nandeeshha H, Pavithran P, Madammanoh T (2009) Effect of 
antihypertensive therapy on serum lipids in newly diagnosed 
esential hypertensive men. Angiology 60:217–220 
100. Pareek A, Karnik N, Salagre SB, Zawar SD, Joglekar VK, 
Chandurkar N, Naik GS (2008) Clinical effectiveness of low-
dose chlorthalidone (6.25 mg) + atenolol combination in stage 
I hypertensive patients: a multicenter, randomized, controlled study. Curr Med Res Opin 24:1771–1779 
101. Satia MC, Shukla ML, Goyal RK (1995) Comparative effects of 
atenolol versus nifedipine on serum lipids and other biochemical parameters in diabetic and non-diabetic hypertensive 
subjects. Indian J Physiol Pharmacol 39:237–241 
102. Shobha JC, Kumar TR, Raju BS, Kamath S, Rao M, Harwal, 
Babu A, Bhaduri J (2000) Evaluation of efficacy and safety of 
losartan potassium in the treatment of mild to moderate hyper-
tension as compared to enalapril maleate. J Assoc Physicians 
India 48:497–500 
103. Sumbria M, Negi PC, Sahai AK, Kaundal PK (2014) To com-
pare the effect of telmisartan with metoprol on arterial stiff-
ness in hypertension: prospective randomized parallel group 
trial. Indian Heart J 66:415–421 
104. Sundar S, Rajan AG, Somani PN, Kumar K (1991) The effects of 
antihypertensive agents on the quality of life in Indian 
hypertensives. Acta Cardiol 46:227–232 
105. NCD Global Monitoring Framework (2015) http://www.who.
.int/nmh/global_monitoring_framework/en/. Accessed 30 Nov 2015 
106. He FF, MacGregor GA (2007) Blood pressure is the most 
important cause of death and disability in the world. Eur Heart J 
Suppl 9:B23–B28 
107. Roth GA, Nguyen G, Forouzanfar MH, Mokdad AH, Naghavi M, 
Murray CJ (2015) Estimates of global and regional premature 
cardiovascular mortality in 2025. Circulation 132:1270–1282 
108. Hippius-Cox J, Coupland C, Robson J, Brindle P (2010) 
Derivation, validation, and evaluation of a new QRISK model to 
estimate lifetime risk of cardiovascular disease: cohort study 
using QResearch database. BMJ 341:c6624 
109. Brindle P, May M, Gill P, Cappuccio F, D’Agostino R Sr, 
Fischbacher C, Ebrahim S (2006) Primary prevention of cardio-
diovascular disease: a web-based risk score for seven British 
black and minority ethnic groups. Heart 92:1595–1602 
110. Leenen FH, Dumnais J, McInnis NH, Turton F, Stratchuk L, 
Nemeth K, Moy Lum-Kwong M, Fodor G (2006) Results of the 
Ontario survey on the prevalence and control of hypertension. 
CMAJ 178:1441–1449 
111. SPRINT Research Group, Wright JT Jr, Williamson JD, 
Whelton PK, Snyder JK, Sink KM, Rococo MV, Reboussin DM, 
Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff 
DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, 
Ambrosius WT (2015) A Randomized Trial of intensive versus 
standard blood-pressure control. N Engl J Med 373:2103–2116
112. Flack JM, Sica DA, Bakris G, Brown AL, Ferdinand KC, Grimm RH Jr, Hall WD, Jones WE, Kountz DS, Lea JP, Nasser S, Nesbitt SD, Saunders E, Scisney-Matlock M, Jamerson KA (2010) Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension 56:780–800

113. Eastwood SV, Tillin T, Chaturvedi N, Hughes AD (2015) Ethnic differences in associations between blood pressure and stroke in South Asian and European men. Hypertension 66:481–488

114. Flack JM, Bhatt DL, Kandzari DE, Brown D, Brar S, Choi JW, D’Agostino R, East C, Katzen BT, Lee L, Leon MB, Mauri L, O’Neill WW, Oparil S, Rocha-Singh K, Townsend RR, Bakris G, SYMPLICITY HTN-3 Investigators (2015) An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. J Am Soc Hypertens 9:769–779

115. Angell SY, De Cock KM, Frieden TR (2015) A public health approach to global management of hypertension. Lancet 385:825–827

116. Oparil S, Melino M, Lee J, Fernandez V, Heyrman R (2010) Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther 32:1252–1269